Clinical trial · Interventional
Effects Of Physical Training On Cardiovascular Capacity In Patients Undergoing Chemotherapy For Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Introduction: Cancer treatment, especially chemotherapy and radiotherapy, can lead to cardiovascular dysfunctions, such as a decrease in left ventricular ejection fraction and electrical dysfunction of the heart, which may consequently compromise patients' quality of life. In this context, physical exercise is a beneficial and promising tool, as it can prevent and minimize the deleterious effects of oncological therapies and their complications. Objective: To evaluate the effect of physical exercise on the prevention of cardiovascular diseases (CVD) induced by cancer treatment, analyzing the impact of supervised exercise on cardiovascular function and quality of life. Materials and Methods: This is a clinical trial in which the sample will consist of 60 individuals undergoing cancer treatment, who will be stratified and randomized according to cancer stage classification into two groups: Intervention Group (IG) and Control Group (CG). The intervention will last 12 weeks, during which the IG will receive a prescription for physical exercises based on the FITT principle (frequency, intensity, time, and type), three times per week, while the CG will remain under usual care. Data will be presented using descriptive statistics, tests for two independent samples, and multivariate analysis, comparing the intervention effects between the two groups using R software version 4.3.3. Expected Results: Low incidence of CVD, improved heart rate variability, adherence to the exercise protocol, reduced risk for cardiovascular diseases, improvement in fatigue, functional capacity, and quality of life. Data will be collected at baseline, at the 6th week, and at the 12th week of intervention.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Abnormalities | — | UNRESOLVED | — |
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| physical training | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Experimental group: will undergo routine monitoring and evaluation, without exercise intervention.
- description
- Patients who will not participate in physical exercise programs, but will be monitored under the same clinical and monitoring conditions.
- type
- EXPERIMENTAL
- label
- physical training
- description
- patients undergoing chemotherapy treatment who will perform physical exercise.
- interventionNames
- Other: physical training
Primary outcomes (3)
- measure
- Cardiotoxicity
- timeFrame
- From registration to the end of treatment in 12 weeks
- description
- The biomarkers used for cardiovascular assessment of cancer patients are: ultrasensitive troponin I or T (marker of myocardial injury).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 59 Years
Show eligibility criteria text
* Inclusion Criteria: * Patients with a confirmed diagnosis of cancer who are undergoing chemotherapy treatment with anthracyclines; * No physical exercise intervention for the past 3 months; * Patients in the early or intermediate stages of cancer treatment; * Adult patients (e.g., 18 to 59 years old) to avoid extreme variations in response to physical exercise; * Clinically stable patients, without absolute contraindications to physical exercise (e.g., decompensated heart failure, severe arrhythmias); * Patients able to participate in a supervised physical exercise program during the study period * Exclusion Criteria: * Patients with severe pre-existing cardiac conditions (e.g., advanced cardiomyopathy, unstable angina) that prevent safe exercise practice; * Patients with physical (e.g., inability to walk) or cognitive limitations that prevent participation in the physical exercise program; * Patients undergoing treatments that may interfere with the results (e.g., recent thoracic radiotherapy, use of cardiotoxic agents unrelated to the study); * Patients who already engage in regular and intense physical exercise, as this could interfere with the effects of the intervention.
References
Publications (0)
Data not yet available